Lividomycin is the antibacterial agent produced by Streptomyces lividus. It is aminoglycoside antibiotic. Lividomycin binds to bacterial ribosomes and inhibits protein synthesis. In vitro development of resistance to lividomycin in P. aeruginosa and M. tuberculosis was much slower than that to kanamycin, but was comparable in Staphylococcus aureus. Lividomycin showed a positive protecting effect for the experimental infections in mice with several bacteria such as S. aureus, P. aeruginosa, Klebsiella pneumoniae and Escherichia coli. It was fairly effective for the experimental infection with the kanamycin-resistant strains of E. coli and P. aeruginosa producing the kanamycin-phosphorylating enzyme.

Furegrelate (previously known as U-63557A), a selective orally active thromboxane synthase inhibitor, with potential for the treatment of various diseases including hypertension, thrombosis, and renal disorders, arrhythmias, but these studies were discontinued.

Indoximod is an orally available Indoleamine 2,3-dioxigenase inhibitor. It shows higher potency in reversing IDO-mediated T cell suppression. Indoximod improves the efficacy of multiple chemotherapeutics agents and some immunological checkpoints mediators in Phase I/II clinical studies for metastatic breast cancer, metastatic melanoma, non-small cell lung cancer, primary malignant brain tumors, metastatic pancreatic cancer, as well as metastatic prostate cancer.

Pozanicline is an alpha4-beta2 neuronal nicotinic receptor partial agonist. It had been in phase II clinical trials for the treatment of attention hyperactivity disorder and Alzheimer’s disease. It was tested for the treatment of schizophrenia too. All these studies were discontinued. Modulation of hippocampal learning and memory using Pozanicline in animal model was effective as novel therapeutic strategies for nicotine addiction. However future clinical trial was terminated.